Expression of p21(WAF1/CIP1) in adenocarcinoma of the uterine cervix: A possible immunohistochemical marker of a favorable prognosis

Cancer

Volumn 82, Issue 12, 1998, Pages 2409-2417

  Lu, Xin ^a   Toki, Toshihiko ^a   Konishi, Ikuo ^b   Nikaido, Toshio ^a   Fujii, Shingo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cell cycle regulatory gene products; Cervical adenocarcinoma; Estrogen receptor; p21(WAF1 CIP1); Prognostic factors

Indexed keywords

CYCLIN E; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; GENE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; CELL CYCLE PROTEINS; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; FEMALE; GENES, CDC; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0032525331     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980615)82:12<2409::AID-CNCR15>3.0.CO;2-T     Document Type: Article

References (39)

1. Brand E, Berek JS, Hacker NF. Controversies in the management of cervical adenocarcinoma. Obstet Gynecol 1988;71: 261-9.
2. Leminen A, Paavonen J, Forss M, Wahlström T, Vesterinen E. Adenocarcinoma of the uterine cervix. Cancer 1990;65: 53-9.
3. Kleine W, Rau K, Schwoeorer D, Pfleiderer A. Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 1989;35:145-9.
4. Anton-Culver H, Bloss JD, Bringman D, Lee-Feldstein A, DiSaia P, Manetta A. Comparison of adenocarcinoma and squamous cell carcinoma of the uterine cervix: a population-based epidemiologic study. Am J Obstet Gynecol 1992; 166:1507-14.
5. Saigo PE, Cain JM, Kim WS, Gaynor JJ, Johnson K, Lewis JL Jr. Prognostic factors in adenocarcinoma of the uterine cervix. Cancer 1986;57:1584-93.
6. Goodman HM, Buttlar CA, Niloff JM, Welch WR, Marck A, Feuer EJ, et al. Adenocarcinoma of the uterine cervix: prognostic factors and patterns of recurrence. Gynecol Oncol 1989;33:241-7.
7. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases. Cancer 1990;65:2507-14.
8. Ismail SM, Thomas GA, Ghandour FA, Davies HG, Attanoos R, Williams ED. Oestrogen receptor protein and mRNA in adenocarcinoma of the uterine cervix. Br J Cancer 1992;66: 1150-4.
9. Toki T, Shiozawa T, Hosaka N, Ishii K, Nikaido T, Fujii S. Minimal deviation adenocarcinoma of the uterine cervix has abnormal expression of sex steroid receptors, CA125, and gastric mucin. Int J Gynecol Pathol 1997;16:111-6.
10. Masood S, Rhatigan RM, Wilkinson EW, Barwick KW, Wilson WJ. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix: an immunocytochemical study. Cancer 1993;72: 511-8.
11. Fujiwara H, Tortolero-Luna G, Mitchell MF, Koulos JP, Wright TC Jr. Adenocarcinoma of the cervix: expression and clinical significance of estrogen and progesterone receptors. Cancer 1997;79:505-12.
12. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996; 42:858-68.
13. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki- ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 1994;59:601-6.
14. Tsuda H, Jiko K, Tsugane S, Yajima M, Yamada T, Tanemura K, et al. Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix. Jpn J Cancer Res 1995;86:1049-53.
15. Oka K, Arai T. MIB1 growth fraction is not related to prognosis in cervical squamous cell carcinoma treated with radiotherapy. Int J Gynecol Pathol 1996;15:23-7.
16. Pitt MA, Hale RJ, Buckley CH. The distribution of type IV collagen in invasive carcinoma of the uterine cervix. Histopathology 1992;20:139-43.
17. Mitchell KM, Hale RJ, Buckley CH, Fox H, Smith D. Cathepsin-D expression in cervical carcinoma and its prognostic significance. Virchows Arch A Pathol Anat Histopathol 1993;422:357-60.
18. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, et al. Prognostic significance of the overexpression of c-erb B-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994;73:148-53.
19. Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, et al. Altered expression of nm23-H1 and c-erb B-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995;75:2523-9.
20. Sherr CJ. Mammalian G1 cyclins. Cell 1993;73:1059-65.
21. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sei USA 1995;92:5386-90.
22. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, De-Caprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A 1996;93:15215-20.
23. Dou Q-P, Pardee AB, Keyomarsi K. Cyclin E: a better prognostic marker for breast cancer than cyclin D? Nat Med 1996;2:254.
24. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression: a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996;74:874-80.
25. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
26. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
27. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
28. INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 1997;74:57-63.
29. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-5.
30. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, et al. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 1997;107:684-91.
31. WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 1997;75:1617-20.
32. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecological cancer. Volume 20. Stockholm: FIGO, 1988.
33. Wright TC, Ferenczy A, Kurman RJ. Carcinoma and other tumors of the cervix. In: Kurman RJ. Blaustein's pathology of the female genital tract. 4th edition. New York: Springer-Verlag, 1994:279-326.
34. FIGO news. Corpus cancer staging. Int J Gynecol Obstet 1989;28:190.
35. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
36. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. Wafl: a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
37. waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol 1997;16:149-55.
38. WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. Pathol Int 1997;47:470-7.
39. Cip1 in muscle and other terminally differentiating cells. Science 1995;267: 1024-7.